Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin

By Sühs Kurt-Wolfram   Papanagiotou Panagiotis   Hein Katharina   Pul Refik   Scholz Kerstin   Heesen Christoph   Diem Ricarda  

International Journal of Molecular Sciences, Vol. 17, Iss. 10, 2016-09 ,pp. : 1666-1666

MDPI

Access to resources Recommend Favorite

Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens

By Rodi Maria   Dimisianos Nikolaos   de Lastic Anne-Lise   Sakellaraki Panagiota   Deraos George   Matsoukas John   Papathanasopoulos Panagiotis   Mouzaki Athanasia  

International Journal of Molecular Sciences, Vol. 17, Iss. 9, 2016-08 ,pp. : 1398-1398

MDPI

Access to resources Recommend Favorite

The Role of Neurotrophins in Multiple Sclerosis—Pathological and Clinical Implications

By Kalinowska-Lyszczarz Alicja   Losy Jacek  

International Journal of Molecular Sciences, Vol. 13, Iss. 10, 2012-10 ,pp. : 13713-13725

MDPI

Access to resources Recommend Favorite

Dendritic Cells and Multiple Sclerosis: Disease, Tolerance and Therapy

By Mohammad Mohammad G.   Hassanpour Masoud   Tsai Vicky W. W.   Li Hui   Ruitenberg Marc J.   Booth David R.   Serrats Jordi   Hart Prue H.   Symonds Geoffrey P.   Sawchenko Paul E.   Breit Samuel N.   Brown David A.  

International Journal of Molecular Sciences, Vol. 14, Iss. 1, 2012-12 ,pp. : 547-562

MDPI

Access to resources Recommend Favorite

Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study

By Zwicker Stephanie   Lira-Junior Ronaldo   Höög Charlotte   Almer Sven   Boström Elisabeth A.  

International Journal of Molecular Sciences, Vol. 18, Iss. 8, 2017-08 ,pp. : 1827-1827

MDPI

Access to resources Recommend Favorite